| 摘要 |
<p>Remedies for graft rejection reactions in GVHD and organ transplantation which are drugs containing as the active ingredient retinoic acid receptor (RAR) agonists typified by 9-(4-methoxy-2,3,6-trimethyl-phenyl)-7,8-dimethylnona-2,4,6,8-tetraen-1-oic acid, 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphthalen-2-yl)propenyl]benzoic acid, 4-{2-[5-(4,7-dimethylbenzofuran-2-yl)pyrrolyl]}benzoic acid, 4-{2-[5-(5-chloro-7-ethylbenzofuran-2-yl)pyrrolyl]}benzoic acid and 4-{2-[5-(4,7-dimethylbenzothiophen-2-yl)-pyrrolyl]}benzoic acid.</p> |
